Business

bioLytical Laboratories Inc. is licensed by Health Canada for the iStatis COVID-19 Antigen Test, a Canadian business journal.

  • From the INSTI® manufacturer, bioLytical has announced a new platform, iStatis. It was created to give everyone in the world access to trusted tests.
  • bioLytical has been approved by Health Canada to sell the iStatis COVID-19 antigen test throughout Canada for professional use in a point-of-care environment.
  • The tests are portable, can be run with many settings, and the results are easy to understand.
  • Test performance in clinical studies showed high accuracy with industry-leading sensitivity and specificity
  • bioLytical quality system is MDSAP and ISO13485 certified

Richmond, British Columbia, March 7, 2022 (GLOBE NEWSWIRE) — BioLytical Laboratories Inc, a global leader in rapid in-vitro medical diagnostics. (“BioLytical”) today announced the launch of a new testing platform, iStatis. Obtained Health Canada approval for iStatis COVID-19 AntigenTest, enabling immediate entry into the Canadian market.

bioLytical is launching iStatis on the basis of the innovative INSTI® test platform, continuously creating reliable access to tests. By adding additional immunoflow technology to the portfolio, bioLytical can reach more people with COVID-19 antigen testing, which provides industry-leading accuracy and peace of mind.

Rob Mackie, CEO of bioLytical, said: “This new platform will extend reach and provide more equitable access to tests. The lack of available antigen tests gives Canadians the opportunity to receive reliable and reliable tests. had.”

Rapid testing is a useful tool in the fight against pandemics and provides additional ways to identify infections and reduce the spread of the virus. Performing regular, rapid tests provide an additional layer of protection against the spread of the virus, along with other public health measures such as physical distance, masking, and hand washing. As new variants are expected to continue, testing will continue to play an essential role in reducing the spread of the virus and keeping Canadians safe at home, at work and in society.

Canada needs secure access to reliable and reliable inspections as COVID-19 is expected to remain. Due to overwhelming national health systems, lack of access to PCR tests, and low supply of rapid tests, the iStatis COVID-19 antigen test identifies infections and makes Canadians a safe and informed decision regarding health. Helps to make a difference. The iStatis COVID Antigen Test, with its high accuracy, portability and ease of use, allows medical professionals to test in multiple environments, reducing the burden on busy hospitals and medical facilities.

bioLytical manufactures iStatis COVID-19 Antigen Tests at an MDSAP and ISO 13485 accredited facility in Richmond, British Columbia, for sale and distribution throughout Canada. As a world leader in ultra-rapid infection diagnosis, bioLytical is committed to ensuring that the iStatis COVID-19 Antigen Test Kit is available to Canadians to know their condition.

bioLytical Laboratories Inc. is a Canadian private company focused on the research, development and commercialization of rapid in vitro medical diagnostics using its unique INSTI® technology platform and its lateral flow line, iStatis. .. bioLytical has won several regional and industry awards, including the 2019 BC Exporter of the Year. It has been named to Lifesciences BC’s Growth Stage Med Tech Company of the Year and has been listed as one of BC’s fastest growing companies for the fifth consecutive year. Globe and Mail’s fast-growing companies are listed in 2020. bioLytical moved to a very large, state-of-the-art facility in Richmond, British Columbia in 2020 to meet the tremendous growth achieved through the team. The INSTI® series, which provides accurate results within 1 minute, includes INSTI® HIV-1 / HIV-2 antibody tests, INSTI® multiplex HIV Syphilis Ab tests, INSTI® HIV self-tests, and INSTI® Covid-19 antibody tests. , And INTI® HCV antibody test. bioLytical sells products in Europe, North America, South America, Africa, and Asia. In 2022, bioLytical launched iStatis. This is a new immunoflow test platform for creating additional access to tests around the world.

By providing accurate results in real time, INTI® and iStatis deliver meaningful results to healthcare professionals, patients, and public health organizations around the world, addressing some of the world’s most serious healthcare challenges. Is an important partner in. For more information, please visit www.istatis.com, www.insti.com and www.biolytical.com.

References
https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/testing-screening-contact-tracing/workplace.html

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d449568c-b104-4fd8-8eb7-e5ea5893d807.


CBJ News Maker

bioLytical Laboratories Inc. is licensed by Health Canada for the iStatis COVID-19 Antigen Test, a Canadian business journal.

Source link bioLytical Laboratories Inc. is licensed by Health Canada for the iStatis COVID-19 Antigen Test, a Canadian business journal.

Related Articles

Back to top button